What question did this study set out to answer?

To assess the therapeutic efficacy of intracerebral AAV-mediated co-delivery of sulfamidase and SUMF1 genes in resolving central nervous system lesions and deficits in an MPS-IIIA mouse model.

August 27, 2007Human Molecular Genetics

Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes

View Full Paper

Ask AI

Bookmark

Authors

AFAlessandro FraldiCeinge Biotecnologie Avanzate (Italy)KHKim M. HemsleyFlinders University ACAllison C. CrawleySouth Australia Pathology

Discussion

Member takes

Implication

Animal study demonstrates functional neurological recovery in an MPS-IIIA mouse model, indicating the therapeutic promise of dual-gene intracerebral AAV delivery.

Key Points

To assess the therapeutic efficacy of intracerebral AAV-mediated co-delivery of sulfamidase and SUMF1 genes in resolving central nervous system lesions and deficits in an MPS-IIIA mouse model.
Injected AAV2/5-CMV-SGSH-IRES-SUMF1 or control AAV2/5-CMV-GFP vectors directly into the lateral ventricles of newborn MPS-IIIA and normal control mice.
Assessed enzymatic sulfamidase activity, lysosomal storage accumulation, and neuroinflammatory markers across transduced brain regions.
Evaluated functional neurobehavioral recovery through cognitive and motor performance testing.
Co-expression of SGSH and SUMF1 produced a synergistic, stable, and significant elevation of sulfamidase activity across multiple murine brain regions.
Vector administration resulted in a visible reduction of lysosomal storage burden and inflammatory markers within transduced brain tissues.
Treated MPS-IIIA mice exhibited functional behavioral improvements in both motor and cognitive performance domains.

Cite This Study

Fraldi et al. (2007) studied this question.

synapsesocial.com/papers/6a729aeeac440176ef2ac1a5 https://doi.org/10.1093/hmg/ddm223

View Full Paper

Ask AI

Bookmark

Implication

Animal study demonstrates functional neurological recovery in an MPS-IIIA mouse model, indicating the therapeutic promise of dual-gene intracerebral AAV delivery.

Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes

Discussion

Member takes

Implication

Key Points

Cite This Study

Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider